WO2018100581A9 - Composé de traitement du diabète sucré de type 2 et de la résistance à l'insuline - Google Patents
Composé de traitement du diabète sucré de type 2 et de la résistance à l'insuline Download PDFInfo
- Publication number
- WO2018100581A9 WO2018100581A9 PCT/IL2017/051307 IL2017051307W WO2018100581A9 WO 2018100581 A9 WO2018100581 A9 WO 2018100581A9 IL 2017051307 W IL2017051307 W IL 2017051307W WO 2018100581 A9 WO2018100581 A9 WO 2018100581A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- diabetes mellitus
- insulin resistance
- mellitus type
- type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL249355A IL249355B (en) | 2016-12-01 | 2016-12-01 | A compound for the treatment of type 2 diabetes and insulin resistance |
IL249355 | 2016-12-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2018100581A2 WO2018100581A2 (fr) | 2018-06-07 |
WO2018100581A9 true WO2018100581A9 (fr) | 2018-07-26 |
Family
ID=58669510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2017/051307 WO2018100581A2 (fr) | 2016-12-01 | 2017-11-30 | Composé de traitement du diabète sucré de type 2 et de la résistance à l'insuline |
Country Status (2)
Country | Link |
---|---|
IL (1) | IL249355B (fr) |
WO (1) | WO2018100581A2 (fr) |
-
2016
- 2016-12-01 IL IL249355A patent/IL249355B/en active IP Right Grant
-
2017
- 2017-11-30 WO PCT/IL2017/051307 patent/WO2018100581A2/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
IL249355B (en) | 2018-05-31 |
WO2018100581A2 (fr) | 2018-06-07 |
IL249355A0 (en) | 2017-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3781147A4 (fr) | Insuline sensible au glucose | |
EP3587399A4 (fr) | Composé, matériau électroluminescent et élément électroluminescent | |
EP3148571A4 (fr) | Composition utilisable en vue du traitement du diabète sucré et contenant de l'insuline et un double agoniste du glp-1/glucagon | |
EP3385255A4 (fr) | Composé fongicide, composition fongicide, leur préparation et leur utilisation | |
EP3268448A4 (fr) | Composé électrochromique, composition électrochromique, élément électrochromique et élément d'obscurcissement électrochromique | |
EP3112439A4 (fr) | Substance luminescente, élément organique luminescent et composé associé | |
EP3310877A4 (fr) | Composé électrochromique, composition électrochromique et élément d'affichage électrochromique | |
EP3448417A4 (fr) | Conjugués dimères d'insuline-incrétine | |
EP3246326A4 (fr) | Composé, mélange le comprenant, composition et dispositif électronique organique | |
EP3506964A4 (fr) | Seringue contraignante | |
EP3538141A4 (fr) | Ligand ilt3 | |
EP3561023A4 (fr) | Matériau luminescent, composé et élément luminescent organique | |
EP4086280A4 (fr) | Dérivé d'insuline | |
EP3341404A4 (fr) | Nouveaux analogues d'insuline et leur utilisation | |
EP3155017A4 (fr) | Produits pharmaceutiques peptidiques améliorés contre l'insulinorésistance | |
EP3458457A4 (fr) | Composé organique électroluminescent, matériau organique électroluminescent et dispositif organique électroluminescent les comprenant | |
EP3122183A4 (fr) | Composition herbicide, procédé pour sa préparation et son utilisation | |
EP3511321A4 (fr) | Élément électroluminescent organique, et matériau électroluminescent et composé destiné à être utilisé dans celui-ci | |
EP3137572A4 (fr) | Composé électrochromique, composition électrochromique, élément d'affichage et élément d'obscurcissement | |
EP3542777A4 (fr) | Composition médicinale pour canal radiculaire | |
EP3280450A4 (fr) | Conjugués d'insuline sensibles au glucose | |
EP3820549A4 (fr) | Ensemble seringue | |
EP3746155A4 (fr) | Ensemble seringue | |
EP3197869A4 (fr) | Composé organique électroluminescent, et matériau organique électroluminescent et dispositif organique électroluminescent le comprenant | |
HK1244216A1 (zh) | 治療2型糖尿病患者 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17876375 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM X1205A DATED 09/10/2019) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17876375 Country of ref document: EP Kind code of ref document: A2 |